---
title: "MediWound stock climbs 4% on Phase 3 study initiation"
date: "2025-02-12 20:17:38"
summary: "MediWound (NASDAQ:MDWD) stock climbed 4% following news that the company has initiated a Phase 3 study of its wound care product EscharEX in the treatment of venous leg ulcers, or VLU. The company noted that the FDA has not approved a product in the treatment category since 1965, according to..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1484581790/image_1484581790.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

MediWound (NASDAQ:[MDWD](https://seekingalpha.com/symbol/MDWD "MediWound Ltd.")) stock climbed 4% following news that the company has initiated a Phase 3 study of its wound care product EscharEX in the treatment of venous leg ulcers, or VLU.

The company noted that the FDA has not approved a product in the treatment category since 1965, [according to a statement](https://seekingalpha.com/pr/19999549-mediwound-initiates-the-value-global-phase-iii-pivotal-trial-of-escharex-for-treatment-of).

An interim sample size assessment is expected to be conducted in mid-2026 after 65% of the patients complete treatment.

The Israeli company also has plans this year to initiate a head-to-head Phase 2 study comparing EscharEx to collagenase in VLU patients. The study is designed to support submission of an FDA Biologics License Application.

[seekalpha](https://seekingalpha.com/news/4407018-mediwound-stock-climbs-4-percent-on-phase-3-study-initiation)
